Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
NewLimit seeks a Scientist/Senior Scientist of In Vivo Pharmacology to lead in vivo studies evaluating epigenetic reprogramming therapeutics. You will design, execute, and interpret PK/PD, efficacy, and dose–response studies across disease models, collaborating with Epigenetic Editing and Predictive Modeling teams to advance candidates.
You will guide study design, CRO management, and data interpretation to inform preclinical decisions and support regulatory-enabling studies as programs progress
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
NewLimit is seeking a talented Scientist / Senior Scientist of In Vivo Pharmacology to join our Translational Sciences team. This critical role designs and executes in vivo studies to evaluate pioneering epigenetic reprogramming therapeutics across our entire portfolio.As a subject matter expert in nonclinical and PK/PD study design, you will lead in vivo pharmacology strategies, collaborate cross-functionally with therapeutic area teams, and directly drive therapeutic candidate selection.
As a Senior Scientist/Scientist on our team, you will:
NewLimit offers generous benefits to ensure our team can focus on our mission:
Salary Range: $130,000 to $180,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at:https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.